Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department,...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-11-01
|
Series: | International Journal of Nanomedicine |
Online Access: | http://www.dovepress.com/oral-fondaparinux-use-of-lipid-nanocapsules-as-nanocarriers-and-in-viv-a8700 |
id |
doaj-1375d1ca280b41f7b0ea481e1a752324 |
---|---|
record_format |
Article |
spelling |
doaj-1375d1ca280b41f7b0ea481e1a7523242020-11-24T23:44:27ZengDove Medical PressInternational Journal of Nanomedicine1176-91141178-20132011-11-012011default29412951Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic studyRamadan ALagarce F, Tessier-Marteau AThomas OLegras P, Macchi LSaulnier PBenoit JPAlyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department, Angers University Hospital, Angers, France; 3Department of Pharmacy, Angers University Hospital, Angers, France; 4Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; 5SCAHU, Animal House, Angers, FranceAbstract: Oral anticoagulant therapy could be advanced using lipid-based nanoparticulate systems. This study examined lipid nanocapsules for their oral absorption potential as the first step in developing oral fondaparinux (Fp) novel carriers. Using phase inversion method and cationic surfactants such as hexadecyltrimethyl ammonium bromide (CTAB) or stearylamine (SA), cationic lipid nanocapsules (cLNCs), loaded with Fp on their surface, were prepared and characterized (zeta potential, size and Fp association efficiency and content). In vivo studies were conducted after single oral increasing doses of Fp-loaded cLNCs (0.5 to 5 mg/kg of Fp) in rats and the concentration of Fp in the plasma was measured by anti-factor Xa activity assay. The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0.2 µg/mL).Keywords: oral anticoagulant, fondaparinux, lipid nanocapsules, bioavailability, pharmacokinetics, ratshttp://www.dovepress.com/oral-fondaparinux-use-of-lipid-nanocapsules-as-nanocarriers-and-in-viv-a8700 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ramadan A Lagarce F, Tessier-Marteau A Thomas O Legras P, Macchi L Saulnier P Benoit JP |
spellingShingle |
Ramadan A Lagarce F, Tessier-Marteau A Thomas O Legras P, Macchi L Saulnier P Benoit JP Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study International Journal of Nanomedicine |
author_facet |
Ramadan A Lagarce F, Tessier-Marteau A Thomas O Legras P, Macchi L Saulnier P Benoit JP |
author_sort |
Ramadan A |
title |
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study |
title_short |
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study |
title_full |
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study |
title_fullStr |
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study |
title_full_unstemmed |
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study |
title_sort |
oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study |
publisher |
Dove Medical Press |
series |
International Journal of Nanomedicine |
issn |
1176-9114 1178-2013 |
publishDate |
2011-11-01 |
description |
Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department, Angers University Hospital, Angers, France; 3Department of Pharmacy, Angers University Hospital, Angers, France; 4Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; 5SCAHU, Animal House, Angers, FranceAbstract: Oral anticoagulant therapy could be advanced using lipid-based nanoparticulate systems. This study examined lipid nanocapsules for their oral absorption potential as the first step in developing oral fondaparinux (Fp) novel carriers. Using phase inversion method and cationic surfactants such as hexadecyltrimethyl ammonium bromide (CTAB) or stearylamine (SA), cationic lipid nanocapsules (cLNCs), loaded with Fp on their surface, were prepared and characterized (zeta potential, size and Fp association efficiency and content). In vivo studies were conducted after single oral increasing doses of Fp-loaded cLNCs (0.5 to 5 mg/kg of Fp) in rats and the concentration of Fp in the plasma was measured by anti-factor Xa activity assay. The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0.2 µg/mL).Keywords: oral anticoagulant, fondaparinux, lipid nanocapsules, bioavailability, pharmacokinetics, rats |
url |
http://www.dovepress.com/oral-fondaparinux-use-of-lipid-nanocapsules-as-nanocarriers-and-in-viv-a8700 |
work_keys_str_mv |
AT ramadana oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy AT lagarcefampnbsptessiermarteaua oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy AT thomaso oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy AT legraspampnbspmacchil oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy AT saulnierp oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy AT benoitjp oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy |
_version_ |
1725498446723416064 |